Skip to content

Radiofrequency ablation, surgical resection, and active observation in thyroid papillary microcarcinoma: a prospective, multicenter, open, observational cohort study

Radiofrequency ablation, surgical resection, and active observation in thyroid papillary microcarcinoma: a prospective, multicenter, open, observational cohort study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200055239
Enrollment
Unknown
Registered
2022-01-04
Start date
2022-01-01
Completion date
Unknown
Last updated
2023-01-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

thyroid papillary microcarcinoma

Interventions

thyroidectomy group :Nil
radiofrequency ablation group :Nil
active observation group :Nil

Sponsors

Xiangya Hospital, Central South University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Aged over 18 years. 2. Before surgery, subjects are willing and able to sign an informed consent form approved by Institutional Review Board (IRB), Ethics Committee (EC) or Ethics Review Board (ERB). 3. According to the judgment of the clinical investigator, the subjects can understand the clinical research and can cooperate with the research process. 4. Thyroid fine needle aspiration confirmed as ''papillary thyroid cancer''. 5. It is a single cancer nodule and the diameter is less than or equal to 1cm. 6. The nodule is >= 2mm from the thyroid capsule.

Exclusion criteria

Exclusion criteria: 1. Chronic diseases, severe liver and kidney insufficiency, acute infectious diseases, autoimmune diseases, malignant tumors and other diseases. 2. The subject has alcohol or drug addiction and/or mental illness, and the investigator believes that it may affect their participation in this study. 3. Has undergone surgery, radiotherapy and other anti-tumor treatments. 4. Suspected lymph node metastasis or distant metastasis.

Design outcomes

Primary

MeasureTime frame
progression-free survival;

Secondary

MeasureTime frame
overall survival;lymph node metastasis rate;distant metastasis rate;recurrence-free survival;

Countries

China

Contacts

Public ContactLi Xinying

Xiangya Hospital Central South University

lixinyingcn@126.com+86 13755110832

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026